益方生物科技（上海）股份有限公司 关于控股股东、实际控制人的一致行动人解除一致行动协议暨权益变动的 提示性公告

Core Viewpoint - The equity change involves the expiration of the concerted action agreement among the controlling shareholders and actual controllers of Yifang Biotechnology (Shanghai) Co., Ltd., leading to a passive dilution of their shareholding due to stock incentive vesting. This change will not affect the company's controlling shareholders or actual controllers, nor its governance structure and ongoing operations [1][8]. Summary by Sections 1. Background of the Concerted Action Agreement - In October 2020, a concerted action agreement was signed by key stakeholders, confirming the actual controllers of the company and establishing that certain parties would act in concert with them on major operational decisions [2]. - A supplementary agreement was signed in June 2021, allowing YAOLIN WANG LLC to join the original agreement without altering the rights and obligations of the other parties [3]. 2. Details of the Termination of Concerted Action - LING ZHANG LLC and LING ZHANG intend to terminate their concerted action relationship due to personal reasons, with LING ZHANG LLC holding 0.54% of the company's shares as of the announcement date [4]. - YAOLIN WANG LLC is changing its manager and will also terminate its concerted action relationship. The new manager, HONG MEI, will not affect the shareholding of YAOLIN WANG LLC, which holds 0.61% of the shares [6][7]. 3. Impact of the Equity Change - Before the equity change, the controlling shareholders and their concerted action parties held a total of 164,263,228 shares, representing 28.58% of the company. Following the vesting of stock incentives, their shareholding was diluted to 28.40%, resulting in a new total of 157,605,902 shares, or 27.26% [9][10]. - The termination of the concerted action relationship will not lead to a change in the controlling shareholders or actual controllers, as the combined shareholding of LING ZHANG LLC and YAOLIN WANG LLC is only 1.15%, which is relatively low and will not significantly impact control [11][12]. 4. Compliance and Future Commitments - The parties involved in the termination of the concerted action relationship will continue to comply with relevant regulations regarding share reduction and commitments made during the initial public offering [13].